DDrare: Database of Drug Development for Rare Diseases

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04401176 (ClinicalTrials.gov)	July 2020	19/5/2020	Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A	Walter Reed National Military Medical Center	NULL	Not yet recruiting	18 Years	N/A	Female	58	Phase 2	NULL
2	JPRN-UMIN000027918	2016/07/01	25/06/2017	Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis		interstitial cystitis	heparin-lidocaine intravesical therapy	Department of Urology and Renal transplantation, Nagasaki University Hospital	NULL	Recruiting	20years-old	80years-old	Male and Female	30	Not selected	Japan
3	JPRN-UMIN000026714	2016/02/26	27/03/2017	RCT study of bladder instillation therapy in patients with refractory interstitial cystitis.		Interstitial cystitis	Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.	Department of Urology, Mitsui Memorial Hospital	NULL	Pending	20years-old	Not applicable	Male and Female	20	Phase 2;Phase 3	Japan
4	NCT02591199 (ClinicalTrials.gov)	September 2015	28/10/2015	Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin	Urigen	NULL	Terminated	18 Years	N/A	All	92	Phase 2	United States
5	NCT01048177 (ClinicalTrials.gov)	December 2012	11/1/2010	A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia	A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia	Vulvodynia	Drug: Bladder instillation with heparin/ lidocaine	Scripps Health	NULL	Withdrawn	18 Years	80 Years	Female	0	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	JPRN-UMIN000006387	2011/11/01	31/10/2011	Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis		interstitital cystitis	Intravesical instillation of heparin, lidocain and bicarbonate	University of Tokushima	NULL	Pending	Not applicable	Not applicable	Male and Female	30	Phase 2	Japan
7	NCT00256542 (ClinicalTrials.gov)	January 2006	17/11/2005	Study of U101 for Bladder Pain and/or Urgency	A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin	Pelvic Pain;Interstitial Cystitis;Bladder Diseases	Drug: Alkalinized Lidocaine-Heparin	Urigen	NULL	Completed	18 Years	N/A	Both	90	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04401176
(ClinicalTrials.gov)

July 2020

19/5/2020

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis;Bladder Pain Syndrome

Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A

Walter Reed National Military Medical Center

NULL

Not yet recruiting

18 Years

N/A

Female

Phase 2

NULL

JPRN-UMIN000027918

2016/07/01

25/06/2017

Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis

interstitial cystitis

heparin-lidocaine intravesical therapy

Department of Urology and Renal transplantation, Nagasaki University Hospital

NULL

Recruiting

20years-old

80years-old

Male and Female

Not selected

Japan

JPRN-UMIN000026714

2016/02/26

27/03/2017

RCT study of bladder instillation therapy in patients with refractory interstitial cystitis.

Interstitial cystitis

Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.
Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.

Department of Urology, Mitsui Memorial Hospital

NULL

Pending

20years-old

Not applicable

Male and Female

Phase 2;Phase 3

Japan

NCT02591199
(ClinicalTrials.gov)

September 2015

28/10/2015

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis;Bladder Pain Syndrome

Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin

Urigen

NULL

Terminated

18 Years

N/A

All

Phase 2

United States

NCT01048177
(ClinicalTrials.gov)

December 2012

11/1/2010

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

Vulvodynia

Drug: Bladder instillation with heparin/ lidocaine

Scripps Health

NULL

Withdrawn

18 Years

80 Years

Female

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000006387

2011/11/01

31/10/2011

Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis

interstitital cystitis

Intravesical instillation of heparin, lidocain and bicarbonate

University of Tokushima

NULL

Pending

Not applicable

Male and Female

Phase 2

Japan

NCT00256542
(ClinicalTrials.gov)

January 2006

17/11/2005

Study of U101 for Bladder Pain and/or Urgency

A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin

Pelvic Pain;Interstitial Cystitis;Bladder Diseases

Drug: Alkalinized Lidocaine-Heparin

Urigen

NULL

Completed

18 Years

N/A

Both

Phase 2

United States